These results are also compatible with a recent meta-analysis including six randomized studies with a total of 2,797 Caucasian patients with NSCLC (not exclusively lung adenocarcinoma), where the estimated frequency of EGFR mutations (exon 19 or 21) was 12.98 %. Here, EGFR is linked to non-small cell lung carcinoma.